In the gleaming labs of Exact Sciences, one of the largest cancer diagnostics companies in the United States, rows of automated machines hum quietly, processing thousands of clinical samples each day. Somewhere among the regulated workflows and high-throughput instrumentation is a woman with gloved hands and careful eyes, making decisions that directly affect the accuracy of cancer diagnoses nationwide.

Her name is Chiamaka Francisca Igweonu. She is one of the many women scientists whose names might not be familiar to the public, but whose work forms the backbone of molecular medicine.

Originally trained in Nigeria, Igweonu began her scientific journey in the government-run labs of Abuja, where she worked on national disease surveillance programs targeting Lassa fever, cholera, and malaria. There, she helped design diagnostic protocols and build biobanks to support public health responses.

Today, she applies that same rigour at Exact Sciences in Wisconsin, helping to ensure that molecular tests for colorectal and other cancers are accurate, timely, and clinically reliable.

Her story reflects a broader pattern: women quietly transforming the landscape of biomedical diagnostics, one assay, one protocol, and one patient sample at a time.

“It’s easy to associate innovation with invention,” said Dr. Amina Caldwell, a senior researcher at the Fred Hutchinson Cancer Centre. “But a huge part of innovation is precision—making sure what already exists works perfectly, every time. Women in labs are doing that work, and doing it exceptionally well.”
Igweonu’s role involves executing and optimising PCR and sequencing-based workflows that feed into some of the company’s most widely used diagnostic tests. While most of the public may know Exact Sciences through advertisements for Cologuard®, few would imagine scientists like Igweonu, who troubleshoot signal noise in fluorescence patterns or monitor the integrity of thermal cyclers—tasks that, if neglected, could lead to misdiagnosis.
The stakes are high, and the margin for error is narrow.

“It’s never just pipetting,” Igweonu said. “It’s knowing what to look for when something doesn’t feel right. It’s catching anomalies before the software does. It’s understanding that behind every run is a person waiting for answers.”

As molecular diagnostics continue to evolve, particularly in fields such as liquid biopsy and multi-cancer early detection, the technical complexity has increased. Similarly, there is a growing need for professionals who can combine scientific knowledge with regulatory discipline. In this space, women are increasingly taking up roles of influence, not always with titles, but with expertise that shapes the flow of clinical operations.

According to a 2023 report from the Association for Molecular Pathology, while women comprise nearly 60% of laboratory staff in clinical diagnostics, they remain underrepresented in executive roles and in public-facing leadership positions. Yet many, like Igweonu, play pivotal roles in maintaining and improving test quality, patient safety, and laboratory efficiency.

“We often work in silos,” said Igweonu. “But the truth is, it’s collaborative. What I do only matters because someone else is doing their part too. I just try to be the person who pays attention to the things others might overlook.”

Beyond her technical contributions, Igweonu has become a mentor figure in her department. New hires are often paired with her during the onboarding process. Colleagues seek her input on troubleshooting and workflow adjustments. When asked about it, she smiles and simply says, “Someone helped me when I was new. I try to return that.”

These quiet forms of leadership—rooted in excellence rather than volume—are what make her and others like her stand out.

“In every high-functioning diagnostics lab I’ve visited, there’s usually a woman behind the scenes making sure things don’t fall apart,” said Dr. Renee Monroe, director of a clinical genomics program in Chicago. “They don’t get headlines, but they make medicine work.”

The visibility of women in science has increased in recent years, thanks to global movements advocating for gender equity in STEM fields. However, much of the attention still focuses on principal investigators, patent holders, and founders. Meanwhile, the women scientists working inside diagnostic operations—those who ensure compliance with FDA standards, validate reagents, and document instrument performance—remain largely unsung.

And yet, their work may be among the most consequential. Diagnostic testing is the starting point for nearly every medical journey. Its reliability determines how quickly patients are diagnosed, how treatment is planned, and how outcomes are measured. The responsibility is enormous.

“Some days you don’t think about it,” said Igweonu. “But other days, you pause and realise that someone is waiting for this result. That keeps you focused.”

As the field of molecular medicine accelerates, driven by artificial intelligence, personalised oncology, and ever-deepening sequencing, the role of skilled, detail-oriented scientists will only become more critical. And if current trends hold, many of them will be women.

Chiamaka Igweonu may not be a household name. But in the quiet precision of her work, she represents a future of diagnostics that is accurate, inclusive, and deeply human.